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Introduction
Alzheimer's disease is the most common form of dementia and is characterised by the presence of amyloid plaques and neurofibrillary tangles in brain tissue (Masters et al., 2015) . Many studies indicate that axonal transport defects play an important role in the pathogenesis of Alzheimer's disease (AD) and overexpression of tau, whose mutation causes some types of frontotemporal dementia, has also been reported to impair axonal transport (Bertrand et al., 2013; Ittner et al., 2008; Majid et al., 2014) . Axonal transport is impaired in several amyloid and tau mouse models, and further impairment of transport increases pathology (Adalbert and Coleman, 2013; De Vos et al., 2008; Millecamps and Julien, 2013) . These include transgenic mouse models overexpressing APP or familial Alzheimer's disease mutant APP (Salehi et al., 2006; Stokin et al., 2005) , mutant presenilin-1 (Lazarov et al., 2007) , and wild-type and FTDP mutant tau (Ishihara et al., 1999; Zhang et al., 2004) . The mechanisms by which the pathological forms of APP, tau, PS1 and amyloid-β (Aβ) disrupt axonal transport are not properly understood. Aβ itself and overexpression of either wild-type and FTDP tau disrupt axonal transport of a variety of cargoes including mitochondria (Hiruma et al., 2003; Rui et al., 2006; Stamer et al., 2002; Zhang et al., 2004) . Live-imaging studies of axonal transport in nervous system tissue have largely focused on mitochondria (Gilley et al., 2012; Mar et al., 2014; Marinkovic et al., 2012; Milde et al., 2015; Misgeld et al., 2007) . We have reported live imaging of peripheral nerve explants of mitochondrial transport in a MAPT P301L/P301L knockin mutant mouse and in normal aging (Gilley et al., 2012; Milde et al., 2015) .
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Axonal swellings are a pathological feature common to human AD and to mice expressing pathogenic forms of amyloid precursor protein (APP) or tau and mice expressing ApoE4 (Lewis et al., 2000; Tesseur et al., 2000; Wirths et al., 2006) . Our earlier study showed that large axonal swellings in one familial Alzheimer's disease (FAD) model, TgCRND8 mice, precede axon loss by many months and that axonal transport may be disrupted specifically at these swellings (Adalbert et al., 2009 ).
TgCRND8 mice inherit a highly aggressive amyloidopathy caused by expression of double mutant amyloid precursor protein (APP; K670N/M671L plus V717F) (Chishti et al., 2001 ), leading to early dystrophic neurites and some cell death (Bellucci et al., 2007) . These findings raise the question of whether boosting axonal transport can alleviate the pathology. Until now, very few methods have been available to enhance axonal transport in vivo, and no studies have addressed whether this type of intervention can alleviate amyloid pathology or the associated axonal damage. There have been encouraging results using microtubule (MT)-stabilising agents, such as those used in the treatment of cancer, to improve axonal transport in tauopathy models (Brunden et al., 2012; Zhang et al., 2005) . These drugs, however, elicit severe side effects, especially as they have to be administered on a chronic basis, including axonal damage in peripheral neuropathy (Boyette-Davis et al., 2013) . In previous work, we have enhanced axonal transport of mitochondria in young mice without adverse effects by knocking in the P301L mutation of MAPT (Gilley et al., 2012) , a mutation causing FTDP-17T in humans (Wolfe, 2009 ). The effect on axonal transport was reversed as animals aged, suggesting other changes during ageing alter how axons react to mutant MAPT. The mice remained healthy during the normal lifespan, with no overt tau pathology, motor, behavioural or memory deficits.
The initial aim of this study, therefore, was to test whether boosting axonal transport M A N U S C R I P T A C C E P T E D , similar to that found in older MAPT P301L/P301L mice. This suggests increasing amyloid beta peptide, or other APP processing products reverses an action of mutant tau on axonal transport and may contribute to a similar switch observed during normal ageing.
Material and methods
Animals
All ), knockin mice were crossed with Mito-P (Thy-1-mitoCFP-P) mice as previously described (Gilley et al., 2012; Misgeld et al., 2007) . Mito-P mice were kindly provided by Prof. Martin
Kerschensteiner (University Munich) and Prof. Thomas Misgeld (TU Munich).
Heterozygous male TgCRND8 mice (Chishti et al., 2001) 
Live imaging of axonal transport and image analysis
Imaging of mitochondrial transport and analysis was done as described previously (Gilley et al., 2012; Milde et al., 2015) . Briefly, mitochondrial movements were imaged in sciatic nerve explants using an Olympus Cell R imaging system (IX81 microscope, Hamamatsu ORCA ER camera, x100 1.45 NA apochromat objective).
Peripheral nerves were used as a surrogate for CNS tissue because in our hands quantitative analysis of axonal transport here is more reproducible than in CNS (Milde et al., 2015) , but the presence of Aβ in peripheral nerves was confirmed (Fig.   2 ). During imaging, tissues were maintained in oxygenated Neurobasal-A medium at 37 ºC in an environment chamber (Solent Scientific). Images were captured using fixed light intensity and camera exposure time settings at a rate of 2 frames per M A N U S C R I P T A C C E P T E D Axonal transport parameters were determined for individual axons using the Difference Tracker set of ImageJ plugins (Andrews et al., 2010) . The principal output of these plugins is the number of moving particles identified in each frame of the image, normalized to axon length (presented as particle count per second per 100 µm axon length).
Histology and staining
Mice were perfused transcardially with 4% phosphate-buffered paraformaldehyde and brains and spinal cords processed as previously described (Adalbert et al., 2009 ). Sagittal brain sections were cut at 50 µm and serial transverse spinal cord sections were cut at 25 µm through the L3-L5 segments using a Leica CM 1850
cryostat. To stain fibrillar amyloid deposits, brain sections were incubated in 0.02% Thioflavine S in TBS for 10 min and then rinsed in 50% ethanol in TBS and 100%
TBS before mounting in Vectashield Mounting Medium. For motor neuron analysis, the spinal cord sections were stained with 0.5% cresyl violet (Adalbert et al., 2006 ).
The excised YFP-H sciatic nerves were incubated in 1% Triton X-100 (Sigma) in 0.1M PBS for 10 min at room temperature, washed extensively in 0.1M PBS and then mounted in Vectashield.
Microscopy and quantitative/qualitative analysis
The stained sections were imaged with an Olympus FV1000 confocal microscope imaging system using a 40x NA 1.3 or 63x NA 1.4 oil immersion objective. Neuronal structures and amyloid plaques were scanned using a multi-track configuration with laser excitation (ex.) lines and emission (em.) filters as follows: Thioflavine S 405nm ex. 475-525nm em. and YFP 488 nm ex. 505-550nm em. Single confocal slices or z-stacks at 0.4-0.5 mm steps were acquired to generate the data images.
Conventional fluorescence imaging was carried out using an Olympus IX 81 inverted microscope coupled to an Olympus U-TV0.5XC digital camera system. Bright-field images of Nissl-stained sections were acquired using an Olympus BX41 upright microscope (40x objective) and MicroPublisher 3.3 camera (QImaging).
The number of amyloid plaques stained with Thioflavin S was determined in six sagittal sections (3 sections/hemisphere) as previously described (Adalbert et al., 2009 ). Amyloid plaques that had at least one YFP-containing axonal dystrophy (cutoff size of the dystrophy 5 µm) in the immediate vicinity were counted as plaques associated with axonal swellings. Cresyl violet stained motor neurons with centrally placed nuclei and cytoplasm rich in rough endoplasmic reticulum were considered normal morphology. Every second section from L3-L5 spinal cord segments was qualitatively analysed. YFP positive axons from sciatic and tibial nerves with no fragmentation or swellings along their length were classified as intact (Beirowski et al., 2004) .
. Aβ ELISA
To determine levels of human Aβ 1-42 in brain and sciatic nerve, samples were analysed using a commercially available ELISA kit ( was then diluted (in the commercial kit dilution buffer) before undergoing ELISA.
Briefly, samples were incubated with Aβ detection antibody for 3 h at RT then thoroughly washed. HRP-conjugated antibody was added to sample wells for 30 min.
After another wash step, samples were incubated with stabilised chromogen for 30 min. The reaction was stopped using an acid-based stop solution and absorbance read at 450 nm using a PheraStar FS plate reader. Samples were run with a standard curve (4-parameter fit) to obtain a concentration readout. Final concentration is given as ng of Aβ per g of tissue (Harwell and Coleman, 2016) .
Immunohistochemistry and Gallyas staining
Mouse brains were fixed in 10% formalin for 24 hours before embedding in paraffin.
7 µm thick tissue sections were stained with the Gallyas silver staining method to identify neurofibrillary tangles as reported previously (Gilley et al., 2012; Kuninaka et al., 2015) . They were examined with a Zeiss Axioplan microscope and digital images acquired using an AxioCam HRc camera.
The immunohistochemical labeling was performed using the ABC method. Sections were treated with 0.3% H 2 O 2 to inhibit endogenous peroxidase and then blocked in 10% vol/vol normal horse serum in TBS (0.01 M Tris, 0.15 M NaCl, pH 7.4). After overnight incubation with diluted PHF-1 or AT8 antibodies (Innogenetics), sections were incubated with biotin-conjugated horse anti-mouse antibodies followed by ABC M A N U S C R I P T
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Statistical analysis
Statistical tests, as described in the figure legends, were performed using Prism software (GraphPad Software Inc, La Jolla, CA, USA). A p value of >0.05 was considered not significant (ns) and *p < 0.05, **p < 0.01, and ***p < 0.001 was significant.
Results
Enhanced mitochondrial transport in 3-month-old MAPT P301L/P301L knockin mouse peripheral nerves
First, we wanted to confirm whether the enhanced mitochondrial transport found previously in 8-11 months homozygous MAPT P301L tau knockin mice (Gilley et al., 2012 ) was also present in younger, 3 months old homozygous tau knockin mice, an age when TgCRND8 shows substantial axonal swellings and an increasing plaque density (Adalbert et al., 2009) . To test this, we crossed MAPT P301L knockin mice to
Thy-1-mitoCFP-P (Mito-P) mice, which have CFP-labelled mitochondria in a subset of their neurons (Misgeld et al., 2007) . The transport of CFP-labelled mitochondria was assessed in axons of explanted sciatic nerves from 3 months old MAPT P301L/P301L
, MAPT P301L/+ , and MAPT +/+ mice. Peripheral nerves were used because we find quantitative analysis of axonal transport in nerves is more reproducible than in CNS (Milde et al., 2015) . We found that the number of CFP labelled mitochondria moving in an anterograde direction was significantly higher in M A N U S C R I P T
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MAPT P301L/P301L mice relative to wildtypes (Fig 1A) . In MAPT P301L/+ mice there was a trend towards increased mitochondrial transport but the difference was not statistically significant. No significant differences were found for retrograde transport (Fig 1B) and changes in anterograde flux were not accompanied by significant alterations to maximum speed or average speed (not shown). Thus, axons from young 3 months old MAPT P301L/P301L knockin mice show an increase in anterograde mitochondrial flux, similar to older (8-11 months) mice, prior to the reversal of this effect we previously observed in old age (Gilley et al., 2012 ) (Fig 1C) , reminiscent of old MAPT P301L/P301L mice without mutant APP (Gilley et al., 2012) . Retrograde mitochondrial transport also declined but this was not statistically significant in our sample ( Fig 1D) and average speed of transport was unaltered (not shown). No significant differences in any transport parameters were identified for TgCRND8 mice heterozygous for the tau knockin mutation (TgCRND8/MAPT P301L/+ ). These data indicate that in the presence of the TgCRND8 mutation, the effect of MAPT P301L/P301L on axonal transport of mitochondria in young animals is reversed, suggesting an interaction between Aβ, or other APP processing products, and mutant tau that resembles the effect of normal ageing. TgCRND8 mice and found that Aβ 1-42 is present in peripheral nerves, at the age when the axonal transport measurements were conducted ( Fig. 2A) . However, the levels were less than 10% of those in brain of the same animals (Fig. 2B) . This suggests the use of peripheral nerves as a surrogate for CNS tissue in this study could underestimate the effect of Aβ, or other APP processing products, in combination with tau in the CNS. Brain levels of Aβ were not altered by the presence of the MAPT P301L/+ knockin mutation (Fig. 2B) .
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MAPT P301L/P301L knockin mutation does not reduce the number of plaques and the associated axonal swellings in TgCRND8 brains
To test whether the presence of MAPT P301L knockin mutation ameliorates amyloid- /YFP-H mice at 3 months of age. We found that the MAPT P301L/P301L mutation did not significantly reduce the number of amyloid plaques (Fig 3A, C) or the associated axonal swellings in the brains of TgCRND8 mice ( Fig   3B, D) , although as axonal transport was not enhanced in these animals as expected it remains undetermined whether boosting transport can alleviate axonal swellings.
No morphological alterations are present in TgCRND8/MAPT P301L/P301L spinal cord motor neurons and peripheral nerves
Histological analysis of motor neurons from lumbar spinal cord segments L3-L5 and YFP positive axons from sciatic and tibial nerves showed no obvious alterations in 3 M A N U S C R I P T
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13 months old TgCRND8/MAPT P301L/P301L mice. Cresyl violet staining revealed motor neurons with normal morphology with centrally placed nuclei and a cytoplasm rich in rough endoplasmic reticulum (Fig 4A) . Also, YFP positive axons from sciatic and tibial nerves were intact with no fragmentation or swellings along their length (Fig 4B,   C ). These observations show that the reduced anterograde axonal transport of mitochondria in peripheral nerves of TgCRND8/MAPT P301L/P301L mice occurs in morphologically normal axons and spinal cord motor neurons.
Absence of tau pathology
We previously showed that pathological aggregation of hyperphosphorylated tau does not occur in MAPT P301L/P301L tau knockin mice (Gilley et al., 2012) . Similarly in this study no Gallyas-positive neurons or neuronal PHF-1 immunostaining for phosphorylated tau was detected in 6 month old brains even after combining TgCRND8 transgene with MAPT P301L/P301L or MAPT P301L/+ knockin mutation (Fig 5) . Only a puncta like staining of dystrophic neurites around the congo red positive plaques was found (Fig 5A) . Hence the presence of FAD-APP does not induce tau pathology in MAPT P301L tau knockin mice, at least up to the age of 6 months.
Discussion
In this study we confirmed and extended our previous observation of increased anterograde mitochondrial transport in 8-11 months homozygous MAPT P301L knockin mice (Gilley et al., 2012) to 3 months old homozygous knockin mice ( Fig 1A) and to a trend in the same direction in heterozygotes. Retrograde transport (Fig 1B) , maximum speed or average speed in either direction (not shown) were unaltered, and after crossing to TgCRND8 the numbers of plaque-associated axonal swellings M A N U S C R I P T Previous studies indicated that the physiological function of tau is required for aspects of FAD-APP pathogenesis. The block of axonal transport by Aβ oligomers in hippocampal primary cultures requires the presence of tau (Vossel et al., 2010) and FAD-APP-induced behavioral deficits in mice are alleviated by removing tau (Roberson et al., 2007) . Recently it was also reported that mutant tau with markedly reduced microtubule-binding capacity still enabled Aβ-induced axonal transport deficits (Vossel et al., 2015) . We now show that co-expression of
A C C E P T E D
, even at physiological levels, synergistically impairs axonal transport with FAD-APP.
All these studies suggest that different tau genotypes, in the presence of Aβ, can lead to transport impairment.
Our findings support the hypothesis that Aβ and tau converge in axons to influence axonal transport or that tau itself is a downstream target of Aβ on the same pathway.
Previously it was suggested that tau may lie downstream of APP/Aβ or on a necessary pathway that converges onto a common, downstream target (Karran et al., 2011; Morris et al., 2011) . In different neurodegenerative diseases, both in humans and in mice, plaques and tangles can arise independently of one another. In mice, neither FAD-APP nor FTDP-17T mutant tau causes both of these pathological hallmarks. Some human patients show amyloid without tau pathology, and FTDP-17T tau mutations cause tangles without plaques in frontotemporal dementia. These observations are consistent with convergent disease pathways, either of which can cause pathology when sufficiently activated. MAPT P301L knockin mutation does not enhance the generation of Aβ 1-42 in the brains of 3 months old TgCRND8 mice ( Fig   2B) , consistent with previous results using overexpression of tau in FAD-APP expressing cell lines or primary neuronal cultures (Goldsbury et al., 2006) . In addition, when tau deletion reduced cognitive deficits and excitotoxic damage in FAD-APP mice, there was no corresponding reduction in Aβ 1-42 (Roberson et al., 2007) . This finding is important because if the synergistic effect of MAPT P301L knockin tau and FAD-APP were mediated by increasing Aβ 1-42 processing, that would favor a mechanism involving feedback on APP over a common downstream target for Aβ 1-42 and MAPT P301L tau.
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Tau pathology is not a feature of APP or PS1 mutant mice but has been seen when combined with overexpressing tau mutants. We were interested to see whether such pathology could be induced when mutant tau is expressed at physiological levels.
Overexpression of Aβ did not induce pathological aggregation of hyperphosphorylated tau in MAPT P301L tau knockin mice by the age of 6 months, however we cannot rule out the possibility that tau pathology could develop at an older age. The puncta like staining of phosphorylated tau in dystrophic neurites around the plaques we observed in our study (Fig. 5A,B) , was reported previously in mutant APP and APP/PS1 transgenic mice, therefore is unlikely to reflect an action of MAPT mutation (Boutajangout et al., 2004; Kurt et al., 2003; Tomidokoro et al., 2001 ).
It is worth noting that alternative models that overexpress both mutant APP and MAPT P301L show late development of tau tangles; a double transgenic requiring 9 months, and a different 3xTg model not showing pathology until 12 months of age (Lewis et al., 2001; Oddo et al., 2003) . It may be, due to the knockin nature of the MAPT P301L in our model that neurofibrillary pathology cannot develop during the normal lifespan of our mice.
Some evidence suggests that increased tau expression and/or altered tau isoform ratio are more important for the development of neurofibrillary pathology in a mouse than is the presence of an FTDP-17T mutation (Adams et al., 2009; Gotz et al., 2001 ). The presence of tau at physiological levels and with the expected isoform ratios in our MAPT P301L tau knockin mice could be responsible for the absence of tau pathology. In addition, it could be that murine tau has less propensity for M A N U S C R I P T
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17 aggregation in vivo compared to human tau (Allen et al., 2002; Ando et al., 2011; Sahara et al., 2002) .
The decline in axonal transport seen when combining the APP and MAPT P301L mutations may anticipate the age-related effect of MAPT P301L tau mutation alone. As
Aβ levels increase with age even without APP mutation (Lesne et al., 2013) , our double mutants may have modelled this process in younger animals. Thus, we suggest that this Aβ rise could contribute to age-related decline in frontotemporal dementia. It would be important to repeat our observations with other mutant tau knockin mice (e.g., R406W) as well, to know whether axonal transport impairment in the presence of Aβ is a consistent effect of FTDP tau mutations. In addition, it would be interesting to test whether amyloid-independent pathogenic mechanism can also lead to axonal transport impairment observed in our model, by crossing the MAPT P301L tau knockin mice with wild-type human APP overexpressing mice (Mucke et al., 2000) . In these mice the human wild-type APP processing is basically nonamyloidogenic (Simon et al., 2009 ).
Using our mouse model, we found that Aβ 1-42 is present in peripheral nerves at the age when the axonal transport measurements were done ( Fig. 2A) , similar to previous studies in the peripheral nerves of other APP mutant mice (Jolivalt et al., 2012 ). In our model the Aβ 1-42 levels in the peripheral nerves were less than 10% of those in the brains of the same animals, which suggest that the effect of Aβ in combination with tau in the CNS could be much stronger.
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In the presence of the APP mutation, MAPT P301L/P301L knockin failed to enhance axonal transport of mitochondria therefore new strategies have to be used to increase transport (Hinckelmann et al., 2013) . Drugs increasing MT acetylation may be useful to boost axonal transport in AD. Tubulin acetylation is reduced in the brains of patients with AD (Hinckelmann et al., 2013) and in the brains of various mouse models of AD (Govindarajan et al., 2013; Kim et al., 2012) . Studies so far showed that HDAC6 inhibitors reverse the amyloid beta-induced changes in α-tubulin acetylation and mitochondrial trafficking in cultured hippocampal neurons (Kim et al., 2012) and HDAC6 knockout in a mouse model of AD restores α-tubulin acetylation in the brain and cognitive function in AD mice (Govindarajan et al., 2013) . Another approach to improve axonal transport could be to inhibit JNK activity. JNK hyperactivity has been reported in models of AD and the inhibition of JNK activity in vivo was shown to be neuroprotective in animal models (Mehan et al., 2011) . JNK3 inhibition rescued axonal transport defects induced by pathogenic fragments of huntingtin in a squid model of axonal transport (Morfini et al., 2009 ).
In summary, we confirmed and extended our previous observation of an increase in mitochondrial transport in young MAPT P301L knockin homozygous mice to animals aged 3 months and observed a non-significant trend also in heterozygotes. This could represent early consequences of the tau dysfunction that may be relevant to FTDP-17T pathogenesis in humans as they age. Our results demonstrate that 
